A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibit...

Por Brana, I, Berger, R, Golan, T, Haluska, P, Edenfield, J, Fiorica, J, Stephenson, J, Martin, L P, Westin, S, Hanjani, P, Jones, M B, Almhanna, K, Wenham, R M, Sullivan, D M, Dalton, W S, Gunchenko, A, Cheng, J D, Siu, L L, Gray, J E
Publicado no Br J Cancer (2014)